Ocular Therapeutix announced positive Phase 3 SOL-1 trial results for AXPAXLI, showing superior and durable outcomes in treating wet age-related macular degeneration (AMD). The company is advancing regulatory submission plans with the FDA and has initiated enrollment in a long-term extension trial (SOL-X). Financially, Ocular holds $666.7 million in cash, supporting operations into 2028, while continuing progress on additional trials including SOL-R and HELIOS-3. An Investor Day is scheduled for June 17, 2026, to provide further updates on clinical and commercial developments.
Chery Group inaugurated the Rosslyn Plant in South Africa, marking a key step in its global expansion and local market integration. The plant, originally built in 1963, will retain 692 employees and create up to 3,000 supply chain jobs, with producti...
Solana's price is currently testing the $75 to $77 support zone after $120 million worth of SOL tokens were withdrawn from exchanges, reducing immediate sell pressure. Institutional interest grows as Securitize lists tokenized shares on Solana, addin...
Aptos discovered a critical stale-cache, type-confusion bug in its Move VM, which was patched within hours after being reported on February 25, 2026. No user funds were lost, and the exploitability on mainnet was very low. The bug posed a serious ris...
Solana has grown into a leading blockchain ecosystem with high daily active addresses and on-chain transactions, supported by a robust stablecoin infrastructure that fuels DeFi, payments, and trading. Its applications generate sustainable fee revenue...
Zcash (ZEC) has surged 13.3% to $462.33 following a major security fix and upcoming Ironwood network upgrade scheduled for July 21, 2026. The upgrade closes the vulnerable Orchard shielded pool, replacing it with a new audited version to prevent coun...
